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Abstract 
Treatment-resistant schizophrenia (TRS) affects around one third of individuals with schizophrenia. 
Although a number of socio-demographic and clinical predictors of TRS have been identified, data on the 
genetic risk of TRS are sparse. We aimed to investigate the association between the polygenic risk score for 
schizophrenia and treatment resistance in patients with schizophrenia. We conducted a nationwide, 
population-based follow-up study among all Danish individuals born after 1981 and with an incident 
diagnosis of schizophrenia between 1999 and 2007. Based on genome-wide data polygenic risk scores for 
schizophrenia were calculated in 862 individuals with schizophrenia. TRS was defined as either clozapine 
initiation or at least two periods of different antipsychotic monotherapies and still being hospitalized. We 
estimated hazard rate ratios (HRs) for TRS in relation to the polygenic risk score while adjusting for 
population stratification, age, sex, geographical area at birth, clinical treatment setting, psychiatric 
comorbidity, and calendar year. Among the 862 individuals with schizophrenia, 181 (21.0%) met criteria for 
TRS during 4,674 person-years of follow-up. We found no significant association between the polygenic risk 
score and TRS, adjusted HR = 1.13 (95% CI: 0.95-1.35). Based on these results, the use of the polygenic risk 
score for schizophrenia to identify individuals with TRS is at present inadequate to be of clinical utility at 
the individual patient level. Future research should include larger genetic samples in combination with non-
genetic markers. Moreover, a TRS-specific developed polygenic risk score would be of great interest 
towards early prediction of TRS.  
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Introduction 
Treatment-resistant schizophrenia (TRS) is considered to affect approximately one third of all individuals 
diagnosed with schizophrenia. TRS is commonly defined as insufficient treatment response despite at least 
two different antipsychotic treatment courses of adequate dose and duration.1-3  
It has been shown, that individuals with a family history of psychosis are more likely to poorly respond to 
antipsychotic drugs,4-6 suggesting a genetic influence in the development of TRS. This is supported by 
previous research indicating that variants in the gene coding for the Dopamine D2 receptor (DRD2) may be 
predictive of response to antipsychotic drugs in first-episode schizophrenia.7-9 The DRD2 lies within one of 
the 108 associated regions reported in schizophrenia showing an overlap between genes contributing to 
the genetic risk of schizophrenia and the key target for antipsychotic drugs.10 Schizophrenia is polygenic, i.e. 
influenced by many genetic variants each having a small effect.11 Combining thousands of common variants 
of small effect, weighted by their effect estimates, in a polygenic risk score, provides a measure of genetic 
liability to schizophrenia.12 Data regarding the association of the polygenic risk score for schizophrenia and 
TRS are sparse,13,14 and more evidence is needed to explore this association further. As the social and 
economic costs of TRS are high,15 and an extended duration of insufficiently treated or untreated psychosis 
is associated with poorer prognosis,16 it is important to identify individuals at high risk of TRS to improve 
efficacy and reduce time and morbidity during failed treatments periods. Genetic predictors could 
potentially help to identify such high-risk individuals. 
In this nationwide, population-based follow-up study, we aimed to examine the association between the 
polygenic risk score for schizophrenia and TRS in a Danish cohort of individuals diagnosed with 
schizophrenia. 
Methods  
This was a prospective cohort study using Danish, population-based registers.  
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Data sources 
Danish, population-based registers were linked using the unique personal identification number assigned to 
all Danish citizens. Information on sex, date of birth, death, emigration, and current and past residence in 
Denmark was obtained from the Danish Civil Registration System established in 1968.17 Genetic data were 
extracted from dried blood spots taken in the first days after birth of nearly all infants born in Denmark 
since 1981 and stored in the Danish Newborn Screening Biobank.18 Information on antipsychotic 
medication was obtained from the Danish National Prescription Registry (DNPR) which holds information 
on all prescriptions redeemed from community pharmacies in Denmark since 1995.19 Data on psychiatric 
hospital diagnoses and admissions were extracted from the Psychiatric Central Research Register (PCRR) 
which contains information on all inpatient contacts since 1969 and outpatient contacts since 1995.20  
Study cohort 
The study cohort consisted of all individuals with a first diagnosis of schizophrenia (the International 
Classification of Diseases, Tenth Revision, ICD-10 code F20)21 between 1999 and 2007, born in Denmark 
after May 1, 1981, with a DNA sample available from the Danish Newborn Screening Biobank.18  
Treatment-resistant schizophrenia 
Our measure of TRS was based on data from the DNPR and PCRR. We defined TRS as first occurrence of 
either clozapine initiation or hospitalization due to schizophrenia during antipsychotic treatment within 18 
months after at least two periods of different antipsychotic monotherapy lasting at least 6 weeks each. This 
treatment-based proxy, used in a recent published study,22 builds on international and Danish treatment 
guidelines and the Kane criteria.1,2,23-25  
The polygenic risk score 
The polygenic risk score for schizophrenia was based on genome-wide data from the PGC discovery sample 
and data from the Danish Newborn Screening Biobank. We calculated polygenic risk scores based on the 
summary statistics (effect allele, effect size) derived from the discovery sample. The discovery sample 
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comprised 34,600 schizophrenia cases and 45,986 controls from the PGC Genome-Wide Association Study 
(GWAS) meta-analysis for schizophrenia, excluding the Danish cases.10 We selected SNPs associated at a p-
value threshold of 0.05 or lower. This threshold was chosen in accordance with other studies including 
polygenic risk scores,26 and this less stringent threshold, compared with thresholds used in association 
analysis of single variants, is considered appropriate to achieve a balance between the number of false-
positive and true-positive risk alleles.27 Thereby, we identified a total of 24,755 SNPs.  In our target sample, 
our independent study population, the polygenic risk score was then calculated for each individual as the 
weighted sum of risk alleles at the selected SNPs with the weight being the effect estimates in the discovery 
sample.  
The polygenic risk score, that is approximately normal distributed,28 was converted into a z-score by 
subtracting the mean and dividing by the standard deviation.  
Candidate predictors of TRS 
In one of the models, we included a selected subset of factors that have been shown to be associated with 
TRS.22,29 These factors were sex, age at first diagnosis of schizophrenia, geographical area at birth (born in 
the capital vs born outside the capital), psychiatric comorbidity (any inpatient psychiatric hospitalization in 
the year prior to first diagnosis of schizophrenia), and clinical treatment setting (in- or outpatient at first 
diagnosis of schizophrenia).  
Statistical analysis 
Individuals were followed from the date of their first hospital diagnosis of schizophrenia until TRS, death, 
emigration, or end of study (December 31, 2010), whichever came first. We estimated hazard rate ratios 
(HRs) for the association between the standardized polygenic risk score and the incidence of TRS, and 
adjusted for the candidate predictors listed above and calendar year. All models including the polygenic risk 
score for schizophrenia were additionally controlled for population stratification by including ten first 
genomic principal components.30 
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We conducted several sensitivity analyses to examine the robustness of the results. First, due to the limited 
size of the cohort, we included the residual from a linear regression of the polygenic risk score on the 
candidate predictors instead of including the set of candidate predictors directly into the model. Second, 
we restricted the TRS definition to clozapine initiation only. Third, we restricted the cohort to adult 
individuals (≥18 years at first diagnosis of schizophrenia) since the antipsychotic treatment guidelines as 
well as clinical prescribing practice and response to antipsychotics differ between childhood- and adult-
onset schizophrenia.31,32 Finally, all analyses were repeated with polygenic risk scores calculated based on 
SNPs selected using thresholds of p<0.01 and p<0.1, including 10,622 and 35,792 SNPs, respectively. 
The proportional hazards assumption was checked by diagnostic plots. All statistical analyses were 
performed using SAS 9.3 and Stata 13.  
Results  
We identified 862 individuals diagnosed with schizophrenia with an available DNA sample. Median age at 
first schizophrenia diagnosis was 19 years (inter-quartile range: 17-21 years), 471 (54.6%) were males and 
391 (45.4%) were females. A total of 181 (21.0%) fulfilled the TRS definition during follow-up. They were 
followed for a total of 4,674 person-years resulting in an incidence rate of TRS of 3.87 (95% CI: 3.31-4.44) 
per 100 person-years, and a median follow-up of 5.4 years (inter-quartile range: 4.1-7.1 years). 
Characteristics for these individuals according to TRS are presented in Table 1. The mean standardized 
polygenic risk score was nominally higher among individuals fulfilling the TRS definition (0.24) compared 
with individuals not fulfilling the TRS definition (0.20), but the difference was not statistically significant 
(p=0.58). 
The adjusted hazard rate ratio for TRS associated with one standard deviation increase in the polygenic risk 
score was 1.13 (95% CI: 0.95-1.35). Only adjusting for population stratification, the estimate was down to 
1.02 (95% CI: 0.88-1.17) (Table 2).  
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We also evaluated the HRs obtained for some of the known predictors for TRS in our analyses in order to 
qualify the validity of our dataset. In this cohort, the factors female sex, psychiatric comorbidity, and being 
inpatient at first diagnosis of schizophrenia were significantly associated with increased rate of TRS, 
whereas no significant associations were found for age at first schizophrenia diagnosis and capital birth 
(Table 2).  
When including the residual of a linear regression of the polygenic risk score on the candidate predictors, 
the association between the polygenic risk score and TRS was virtually unchanged, adjusted HR=1.12 (95% 
CI: 0.93-1.33).  
When restricting the TRS definition to clozapine initiation only, the association remained statistically 
insignificant, but the adjusted HR was slightly higher, HR=1.23 (0.97-1.56) (Supplementary Table 1).  
We further examined the association restricted to adult individuals (≥18 years at first diagnosis of 
schizophrenia), although with a weaker statistical precision.  Among this subset of individuals (n=584), we 
found no association between the polygenic risk score and TRS, adjusted HR=1.01 (0.80-1.27) 
(Supplementary Table 2).  
Finally, we repeated the analysis with polygenic risk scores calculated based on SNPs selected using 
different thresholds, and found similar results. Adjusted HRs for TRS were 1.09 (95% CI: 0.92-1.29) for 
p<0.01 and 1.17 (95% CI:  0.98-1.41) for p<0.1. 
Discussion 
This study provided no statistically significant evidence for an association between an increased polygenic 
risk score for schizophrenia and TRS.  
Our study is in agreement with two other studies. In a study from Australia by Martin and Mowry, no 
statistically significant association between the polygenic risk score and TRS was found, where TRS was 
defined as non-response to antipsychotics inspired by the modified Kane criteria.14 Similarly, in a study 
from Iceland by Sigurdsson and Ingimarsson, the polygenic risk score did not differ with regard to clozapine 
use (Abstract for the 23rd European Congress of Psychiatry: Polygenic Risk Scores and Metabolic Side 
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Effects in Clozapine Treatment of Schizophrenia, 2015;30(Supplement 1):93). Another study found crude 
statistically significantly increased polygenic risk score among people with schizophrenia treated with 
clozapine, but the association did not remain significant after adjustment for clinical variables.13 In our 
study, the HR estimate was insignificantly but nominally increased when lifetime clozapine treatment was 
used as a proxy for TRS. In summary, the evidence for an association between the polygenic risk score for 
schizophrenia and TRS is still sparse and not fully clarified.  
The main strengths of the setting of this study are the uniformly organized Danish health care system 
allowing a population-based design and the ability to link different data sources with prospectively 
collected data independent of the study hypothesis and with virtually complete follow-up.  
The validity of the schizophrenia diagnosis in the registers is high,33 but by only including people with 
schizophrenia with an available DNA sample, the sample was relatively young, and this may have 
introduced selection bias, thus limiting generalizability. The relatively young cohort might explain why we 
did not observe significant associations between TRS and age at first schizophrenia diagnosis and capital 
birth, as opposed to other studies,14,22,29 but in line with a study on early-onset schizophrenia and 
clozapine.31 Moreover, in accordance with studies of similar sample sizes, no association was found 
between TRS and sex and family history of schizophrenia.13,14 
Based on register data with lack of information on in-hospital drug treatment and clinical scores, TRS 
cannot be identified without misclassification, as discussed elsewhere.22 Still, we believe that this proxy 
definition of TRS, based not only on clozapine initiation but on history of different AP treatment is closer to 
the theoretical definition of TRS based on clinical guidelines which, in turn, are based on the modified Kane 
criteria.1,2 Nevertheless, sensitivity analysis restricting the TRS definition to clozapine initiation did not alter 
our conclusion. 
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The ability of our study to detect an association between the polygenic risk score for schizophrenia and TRS 
may also be hindered by the relatively small sample size. This small sample size also only allowed adjusting 
for few factors. The estimate was largely unaffected by adjustment for candidate predictors. 
In spite of lack of association between the polygenic risk score and TRS, there might still be a genetic 
influence on TRS. An association between total copy number duplication burden genome wide and TRS has 
been found,14 and people with TRS have been shown to have an excess of rare disruptive variants in gene 
targets of antipsychotics.11 While genetic variations at the DRD2 have been associated with treatment 
response in schizophrenia,7-9 these variants alone only have a modest effect and are not clinical useful. The 
polygenic risk score thus remains a potentially useful tool for genetic risk models. Previously, the polygenic 
risk score for schizophrenia has been shown to be able to predict case-control status in independent 
samples, although the sensitivity and specificity of the polygenic risk score for schizophrenia were found to 
be low.10 The predictive accuracy of the scores may be optimized by accounting for the effects of linkage 
disequilibrium,34 and thus the scores may also improve the prediction of TRS.  
Conclusion 
The polygenic risk score for schizophrenia was not statistically significantly associated with TRS. This result 
suggests that the predictive power of this polygenic risk score in identifying TRS individuals is at present 
inadequate to be of clinical utility at the individual patient level. For future research on genetic markers for 
TRS and potential implementation in clinical practice, larger genetic samples and possible combination with 
non-genetic markers will be required. Moreover, development and validation of a TRS-specific polygenic 
risk score would be of great importance. 
Supplemental material 
Supplemental material is available. 
Funding 
This work was supported by the European Community’s Seventh Framework Programme (FP7/2007-2013) 
(grant number 279227); and the Lundbeck Foundation, Denmark (grant number R155-2014-1724).  
11 
 
Dr MacCabe was funded by the NIHR Biomedical Research Centre for Mental Health at King’s College 
London and the South London and Maudsley NHS Foundation Trust. Dr Meier received further funding from 
the Mental Health Services, Capital Region, Copenhagen, Denmark. All other authors have declared that 
there are no conflicts of interest in relation to the subject of this study. 
Acknowledgements 
This study was approved by the Danish Data Protection Agency and the Danish Health and Medicines 
authority. 
 
 
 
 
12 
 
1. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A 
double-blind comparison with chlorpromazine. Arch.Gen.Psychiatry. 1988;45(9):789-796. 
2. Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 
2001;50(11):898-911. 
3. NICE project team GDG. NICE guideline 178. Psychosis and schizophrenia in adults: treatment and 
management. guidance.nice.org.uk/cg178: National Institute for Health and Care Excellence (NICE), 
London and Manchester, UK;2014. 
4. Crespo-Facorro B, de la Foz VO, Ayesa-Arriola R, et al. Prediction of acute clinical response following 
a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP 
study. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:162-167. 
5. Hassan AN, De Luca V. The effect of lifetime adversities on resistance to antipsychotic treatment in 
schizophrenia patients. Schizophr Res. 2015;161(2-3):496-500. 
6. Huber CG, Naber D, Lambert M. Incomplete remission and treatment resistance in first-episode 
psychosis: definition, prevalence and predictors. Expert.Opin.Pharmacother. 2008;9(12):2027-2038. 
7. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained 
response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry. 
2006;163(3):529-531. 
8. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as 
predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 
2008;9(10):1437-1443. 
9. Zhang JP, Robinson DG, Gallego JA, et al. Association of a Schizophrenia Risk Variant at the DRD2 
Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull. 
2015;41(6):1248-1255. 
10. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 
schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427. 
11. Ruderfer DM, Charney AW, Readhead B, et al. Polygenic overlap between schizophrenia risk and 
antipsychotic response: a genomic medicine approach. Lancet Psychiatry. 2016. 
12. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of 
schizophrenia and bipolar disorder (International Schizophrenia Consortium). Nature. 
2009;460(7256):748-752. 
13. Frank J, Lang M, Witt SH, et al. Identification of increased genetic risk scores for schizophrenia in 
treatment-resistant patients. Mol Psychiatry. 2015;20(2):150-151. 
14. Martin AK, Mowry B. Increased rare duplication burden genomewide in patients with treatment-
resistant schizophrenia. Psychol Med. 2016;46(3):469-476. 
15. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of 
treatment-resistant schizophrenia: a systematic literature review. Int.Clin.Psychopharmacol. 
2013;29(2):63-76. 
16. Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis 
and outcome: an eight-year prospective study. Schizophr.Res. 2005;79(1):85-93. 
17. Pedersen CB. The Danish Civil Registration System. Scand.J.Public Health. 2011;39(7 Suppl):22-25. 
18. Norgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening 
Biobank. J Inherit Metab Dis. 2007;30(4):530-536. 
19. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand.J.Public 
Health. 2011;39(7 Suppl):38-41. 
20. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand.J.Public 
Health. 2011;39(7 Suppl):54-57. 
21. Webb RT, Antonsen S, Mok PL, Agerbo E, Pedersen CB. National Cohort Study of Suicidality and 
Violent Criminality among Danish Immigrants. PLoS.One. 2015;10(6):e0131915. 
22. Wimberley T, Stovring H, Sorensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment 
resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016. 
13 
 
23. National Collaborating Centre for Mental H. Schizophrenia: Core Interventions in the Treatment 
and Management of Schizophrenia in Primary and Secondary Care (Update). NICE Clinical 
Guidelines, No. 82 Leicester (UK): British Psychological Society; 2009. 
24. Damkier P, Larsen, J.T., Christensen, A., Nielsen, B. Kliniske retningslinier for behandling med 
antipsykotika [Clinical guidelines for treatment with antipsychotics]. Skizofrenisektoren, Psykiatrisk 
afdeling, Odense Universitetshospital [Section for Schizophrenia, Department of Psychiatry, Odense 
University Hospital]2009. 
25. Glenthøj B, Gerlach, J., Licht, R., Gulmann, N., Jørgensen, O.S. Behandling med antipsykotika. 
Vejledende retningslinjer. [Treatment with antipsychotics. Guidelines]. Dansk Psykiatrisk Selskab 
[Danish Psyhiatric Association]1998. 
26. Agerbo E, Sullivan PF, Vilhjalmsson BJ, et al. Polygenic Risk Score, Parental Socioeconomic Status, 
Family History of Psychiatric Disorders, and the Risk for Schizophrenia: A Danish Population-Based 
Study and Meta-analysis. JAMA Psychiatry. 2015;72(7):635-641. 
27. Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research review: 
Polygenic methods and their application to psychiatric traits. J Child Psychol Psychiatry. 
2014;55(10):1068-1087. 
28. Dudbridge F. Power and predictive accuracy of polygenic risk scores. PLoS Genet. 
2013;9(3):e1003348. 
29. Wimberley T, Pedersen CB, MacCabe JH, et al. Inverse association between urbanicity and 
treatment resistance in schizophrenia. Schizophr Res. 2016. 
30. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components 
analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-
909. 
31. Schneider C, Papachristou E, Wimberley T, et al. Clozapine use in childhood and adolescent 
schizophrenia: A nationwide population-based study. Eur.Neuropsychopharmacol. 2015;25(6):857-
863. 
32. Fink-Jensen A, Rasmussen I, Viuff A, et al. Baggrundsnotat for medicinsk behandling af psykotiske 
tilstande (Background note for medical treatment of psychotic states). 2014. 
33. Uggerby P, Ostergaard SD, Roge R, Correll CU, Nielsen J. The validity of the schizophrenia diagnosis 
in the Danish Psychiatric Central Research Register is good. Dan Med J. 2013;60(2):A4578. 
34. Vilhjalmsson BJ, Yang J, Finucane HK, et al. Modeling Linkage Disequilibrium Increases Accuracy of 
Polygenic Risk Scores. Am J Hum Genet. 2015;97(4):576-592. 
 
 
  
14 
 
Tables 
Table 1: Characteristics for individuals with schizophrenia with a DNA sample available (N=862). 
Characteristics TRS during 
follow-up 
No TRS during 
follow-up 
Total 
N 181 681 862 
Polygenic risk score (mean, SD)  0.24 (1.04) 0.20 (1.01) 0.21 (1.02) 
    
Age at first schizophrenia diagnosis, years (median, 
inter-quartile range) 
19.0 (16.9-20.8) 19.2 (17.0-20.9) 19.1 (17.0-20.9) 
    
Sex, N (%)*    
  Female 101 (55.8%) 290 (42.6%) 391 (45.4%) 
  Male 80 (44.2%) 391 (57.4%) 471 (54.6%) 
    
Geographical area at birth, N (%)    
  Capital 25 (13.8%) 116 (17.0%) 141 (16.4%) 
  Provincial or rural 156 (86.2%) 565 (83.0%) 721 (83.6%) 
    
Treatment setting at first diagnosis of schizophrenia, N 
(%)* 
   
  Inpatient 121 (66.9%) 306 (44.9%) 427 (49.5%) 
  Outpatient 60 (33.1%) 375 (55.1%) 435 (50.5%) 
    
Psychiatric comorbidity in the year prior to first 
diagnosis of schizophrenia, N (%)* 
   
  Yes 91 (50.3%) 208 (30.5%) 299 (34.7%) 
  No 90 (49.7%) 473 (69.5%) 563 (65.3%) 
* p<0.05 for significant difference between individuals with treatment-resistant and non-treatment-resistant schizophrenia.   
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Table 2: Hazard rate ratios (HR) for the event of TRS (crude and adjusted associations with TRS) (N=862). 
 Crude HR (95% CI) Adjusted HR (95% CI)1 
   
Polygenic risk score  1.02 (0.88-1.17) 2 1.13 (0.95-1.35) 2 
Age at first diagnosis of schizophrenia (years) 1.02 (0.97-1.08) 1.02 (0.96-1.08) 
Female 1.68 (1.25-2.25) 1.57 (1.16-2.13) 
Capital birth 0.74 (0.49-1.13) 0.76 (0.48-1.19) 
Inpatient at first diagnosis of schizophrenia 2.15 (1.58-2.93) 2.07 (1.50-2.84) 
Any psychiatric comorbidity in the year prior to first 
diagnosis of schizophrenia 
2.10 (1.57-2.81) 1.86 (1.38-2.51) 
Calendar year 1.02 (0.94-1.10) 1.04 (0.95-1.13) 
1 Adjusted for age, sex, geographical area at birth, treatment setting, psychiatric comorbidity, and calendar year. 
2 Including the first ten genomic principal components to adjust for population stratification. 
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Supplementary material 
Supplementary Table 1: Hazard rate ratios (HR) for the event of clozapine initiation (crude and adjusted associations with 
clozapine initiation) (N=862). 
 Crude HR (95% CI) Adjusted HR (95% CI)1 
   
Polygenic risk score  1.08 (0.90-1.30) 2 1.23 (0.97-1.56) 2 
Age at first diagnosis of schizophrenia (years) 1.06 (0.99-1.13) 1.09 (1.01-1.19) 
Female 1.39 (0.95-2.05) 1.35 (0.91-2.00) 
Capital birth 0.74 (0.43-1.30) 0.81 (0.45-1-46) 
Inpatient at first diagnosis of schizophrenia 2.17 (1.44-3.28) 2.02 (1.32-3.09) 
Any psychiatric comorbidity in the year prior to first 
diagnosis of schizophrenia 
2.28 (1.55-3.35) 1.98 (1.33-2.94) 
Calendar year 0.96 (0.87-1.05) 0.94 (0.84-1.06) 
1 Adjusted for age, sex, geographical area at birth, treatment setting, psychiatric comorbidity, and calendar year. 
2 Including the first ten genomic principal components to adjust for population stratification. 
Supplementary Table 2: Hazard rate ratios (HR) for the event of TRS among adult individuals (crude and adjusted associations 
with TRS) (N=584). 
 Crude HR (95% CI) Adjusted HR (95% CI)1 
   
Polygenic risk score2  0.92 (0.75-1.11) 2 1.01 (0.80-1.27) 2 
Age at first diagnosis of schizophrenia (years) 1.02 (0.91-1.14) 1.07 (0.93-1.22) 
Female 1.28 (0.87-1.86) 1.08 (0.72-1.61) 
Capital birth 0.59 (0.31-1.13) 0.65 (0.34-1.27) 
Inpatient at first diagnosis of schizophrenia 2.29 (1.54-3.40) 2.30 (1.53-3.46) 
Any psychiatric comorbidity in the year prior to first 
diagnosis of schizophrenia 
1.92 (1.32-2.80) 1.74 (1.18-2.58) 
Calendar year 0.98 (0.88-1.09) 0.99 (0.88-1.13) 
1 Adjusted for age, sex, geographical area at birth, treatment setting, psychiatric comorbidity, and calendar year. 
2 Including the first ten genomic principal components to adjust for population stratification. 
